Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

Introduction: One third of depressed patients do not respond adequately to conventional
antidepressants including the selective serotonin reuptake inhibitors (SSRIs). Therefore …

Unlike classic serotonergic antidepressant drugs, ketamine, an NMDA receptor antagonist,
exhibits a rapid and persistent antidepressant (AD) activity, at sub-anaesthetic doses in …

The forced swim test (FST) is a preclinical test to the screening of antidepressants based on
rats or mice behaviours, which is also sensitive to stimulants of motor activity. This work …

Serotonin (5-HT) neurotransmission is thought to underlie mental illnesses, such as bipolar
disorder, depression, autism and schizophrenia. Independent studies have indicated that 5 …

The effects of serotonin (5-HT) on anxiety and depression are mediated by a number of 5-HT
receptors, including autoreceptors that act to inhibit 5-HT release. While the majority of …

Major depression is a heterogeneous disorder, both in terms of symptoms, ranging from
anhedonia to cognitive impairment, and in terms of pathogenesis, with many interacting …

The neurotransmitter serotonin underlies many of the brain's functions. Understanding
serotonin neurochemistry is important for improving treatments for neuropsychiatric …

Modelling of complex psychiatric disorders, eg, depression and schizophrenia, in animals is
a major challenge, since they are characterized by certain disturbances in functions that are …

At sub-anaesthetic doses, ketamine, a non competitive N-methyl-d-aspartate (NMDA)
receptor antagonist, has demonstrated remarkable and rapid antidepressant (AD) efficacy in …